# US 2021/0260167 A1 · Lubricin for use in wound healing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260167 A1
- Document ID: US20210260167A1
- Status: Published application
- Kind: A1
- Application number: 17/253,253
- Filed: 2019-06-21
- Published: 2021-08-26
- Earliest claimed: 2018-06-21
- Assignees: Lubris LLC
- Applicants: Lubris LLC
- Inventors: Roman Krawetz; Saleem Abubacker; Jeffrey Alan Biernaskie; Tannin Avery Schmidt
- Web page: https://patentgrep.com/patent/US20210260167A1

## CPC

- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/351: not condensed with another ring
- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/7036: having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 33/38: Silver; Compounds thereof
- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 38/1709: {from mammals}
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 15/44: Medicaments
- A61L 26/0066: {Medicaments; Biocides}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 27/02: Ophthalmic agents
- A61L 2300/412: Tissue-regenerating or healing or proliferative agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The application relates to uses of the proteoglycan 4 protein, also known as lubricin, in wound healing and tissue regeneration, reducing scar formation, and promoting angiogenesis.

## Claims

### Claim 1

A method of promoting tissue regeneration or wound healing while reducing scar formation comprising administering to a wound or the site of tissue injury in a patient in need thereof a pharmaceutical preparation comprising lubricin.

### Claim 2 (depends on 1)

The method of claim 1, wherein the lubricin is recombinant human lubricin.

### Claim 3 (depends on 1, 2)

The method of any one of claims 1-2, wherein the lubricin has the amino acid sequence of SEQ ID NO:1 or residues 25-1404 of SEQ ID NO:1.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the lubricin has at least 95% amino acid sequence identity with the sequence of SEQ ID NO:1 or residues 25-1404 of SEQ ID NO:1.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the wound or tissue injury is in the eye.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the wound or tissue injury is in the cornea.

### Claim 7 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the wound is present in the epidermis, dermis, and/or hypodermis layer(s) of the skin.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the wound is a cut, puncture, laceration, tear, scrape, or abrasion to the skin, or a surgical incision.

### Claim 9 (depends on 1, 2, 3, 4, 7)

The method of any one of claim 1-4 or 7, wherein the wound is a bruise.

### Claim 10 (depends on 1, 2, 3, 4, 7)

The method of any one of claim 1-4 or 7, wherein the wound is a burn.

### Claim 11 (depends on 1, 2, 3, 4, 7)

The method of any one of claim 1-4 or 7, wherein the wound is a dermal ulcer.

### Claim 12 (depends on 11)

The method of claim 11, wherein the ulcer is decubitus (pressure ulcer), a diabetic ulcer, or an ulcer caused by bacterial infection.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the wound is at a site that is non-articular, non-osseous, and non-osteal and the wound is not in a bone, joint, articular cartilage, tendon or ligament.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the lubricin is provided at a concentration of 1 μg/mL to 1 mg/mL.

### Claim 15 (depends on 14)

The method of claim 14, wherein the lubricin is provided at a concentration of 100 μg/mL.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the lubricin is provide in an amount of 10-150 μg per cm2 of wound area.

### Claim 17 (depends on 16)

The method of claim 16, wherein the lubricin is providing in the amount of 75-100 μg per cm2 of wound area.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the pharmaceutical preparation is administered as a solution, suspension, emulsion, lotion, cream, gel, paste, or ointment.

### Claim 19 (depends on 18)

The method of claim 18, wherein the pharmaceutical preparation is applied topically to the wound.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any on claims 1-19, wherein the pharmaceutical preparation is administered as an impregnate of a wound dressing that is applied to the wound.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the pharmaceutical preparation further comprises an antibiotic or an anti-inflammatory agent or an analgesic agent or is administered with an antibiotic, anti-inflammatory, or analgesic agent.

### Claim 22 (depends on 21)

The method of claim 21, wherein the analgesic agent is lidocaine or benzocaine.

### Claim 23 (depends on 22)

The method of claim 22, wherein the antibiotic is neomycin, polymyxin b, bacitracin, erythromycin, retapamulin, sulfacetamide sodium, mupirocin, pramoxine, silver sulfadiazine, mafenide, or ozenoaxacin.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, comprising administering said pharmaceutical preparation as liquid drops or by injection at the site of the wound.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24, wherein the pharmaceutical preparation does not include hyaluronic acid.

### Claim 26

A pharmaceutical composition for use in promoting tissue regeneration or wound healing while reducing scar formation comprising lubricin.

### Claim 27

A method of inducing angiogenesis at a site in a body of a patient in need thereof, comprising administering a pharmaceutical preparation comprising lubricin to the site in an amount sufficient to induce new blood vessel formation.

### Claim 28 (depends on 27)

The method of claim 27, wherein the lubricin is recombinant human lubricin.

### Claim 29 (depends on 27, 28)

The method of any one of claims 27-28, wherein the lubricin has the amino acid sequence of SEQ ID NO:1 or residues 25-1404 of SEQ ID NO:1.

### Claim 30 (depends on 27, 28, 29)

The method of any one of claims 27-29, wherein the lubricin has at least 95% amino acid sequence identity with the sequence of SEQ ID NO:1 or residues 25-1404 of SEQ ID NO:1

### Claim 31 (depends on 27, 28, 29, 30)

The method of any one of claims 27-30, wherein the lubricin is provided at a concentration of 1 μg/mL to 1 mg/mL.

### Claim 32 (depends on 31)

The method of claim 31, wherein the lubricin is provided at a concentration of 100 μg/mL.

### Claim 33 (depends on 27, 28, 29, 30, 31, 32)

The method of any one of claims 27-32 wherein the lubricin is provided in an amount of 10-150 μg per cm2 area of the site.

### Claim 34 (depends on 27, 28, 29, 30, 31, 32)

The method of any one of claims 27-32, wherein the lubricin is provided in the amount of 75-100 μg per cm2 area of the site.

### Claim 35 (depends on 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 27-34, wherein the lubricin is administered topically to the site.

### Claim 36 (depends on 27, 28, 29, 30, 31, 32, 33, 34)

The method of any one of claims 27-34, wherein the lubricin is administered to the site by injection.

### Claim 37 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 27-36, wherein the pharmaceutical preparation does not include hyaluronic acid.

### Claim 38 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 27-37 wherein the site in the body is the skin or the eye excluding the cornea.

### Claim 39 (depends on 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 27-38, wherein the site in the body is non-articular, non-osseous, and non-osteal and the site is not in a bone, joint, or articular cartilage

### Claim 40

A pharmaceutical composition for use in promoting angiogenesis comprising lubricin.

### Claim 41 (depends on 26, 40)

The pharmaceutical composition of claim 26 or 40 further comprising a pharmaceutically acceptable carrier.

### Claim 42

A method of treating or preventing aberrant wound healing in an eye comprising administering lubricin to an eye suffering from or at risk of aberrant wound healing.

### Claim 43 (depends on 42)

The method of claim 42, wherein the aberrant wound healing is scarring of the cornea.

### Claim 44 (depends on 42)

The method of claim 42, wherein the aberrant wound healing is corneal haze.

### Claim 45 (depends on 42, 43, 44)

The method of any one of claims 42-44, wherein the lubricin is provided at a concentration of 1 μg/mL to 1 mg/mL.

### Claim 46 (depends on 42, 43, 44, 45)

The method of any one of claims 42-45, wherein the lubricin is provided in an amount of 10-150 μg per cm2 based on the size of the wound.

### Claim 47 (depends on 42, 43, 44, 45, 46)

The method of any one of claims 42-46, wherein the lubricin has at least 95% amino acid sequence identity with the sequence of SEQ ID NO:1 or residues 25-1404 of SEQ ID NO:1.

### Claim 48 (depends on 42, 43, 44, 45, 46, 47)

The method of any one of claims 42-47, wherein the lubricin is administered ophthalmically as drops or an ointment.

### Claim 49 (depends on 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 42-48, wherein the lubricin is administered to the eye upon completion of a keratinoplasty, photorefractive keratectomy, laser subepithelial keratomileusis, or laser in situ keratomileusis.
